

To: AmeriHealth Caritas Next Providers

Subject: 4/18/2022 Formulary Changes

Formulary Changes

Effective 4/18/2022, the following products will be added to the formulary:

1. Additions to Tier 2:
 - a. Sodium chloride nebulization solution 3% and 7%
2. Additions to Tier 3:
 - a. Lacosamide oral tablets
3. Additions to Tier 4:
 - a. Budesonide-formoterol inhalers
4. Additions to Tier 5 with prior authorization:
 - a. Xadago
 - b. Vascepa 1 GM oral capsule
 - c. Qulipta
5. Additions to Tier 6 with prior authorization:
 - a. Rinvoq 30 mg and 40 mg extended-release oral tablets
 - b. Hydroxyprogesterone caproate IM vial
 - c. Makena Auto-Injector
 - d. Mayzent 1 mg oral tablet and 0.25 mg starter pack
 - e. Livmarli
 - f. Tavneos

Effective 4/18/2022, the following products will be removed from the formulary:

1. Ruzurgi
2. Symbicort
3. Baclofen 5 mg oral tablet
4. Metipranolol ophthalmic solution
5. Vimpat oral tablets

Effective 4/18/2022, the following products will move tiers on the formulary:

1. Tier 5 with ST to Tier 3
 - a. Fluticasone-salmeterol inhaler (generic AirDuo Resplick)



2. Tier 4 to Tier 5 with step therapy
 - a. Breo Ellipta
3. Tier 4 with PA to Tier 5 with PA
 - a. Aimovig Auto-injector
4. Tier 3 with QL to Tier 2 with QL
 - a. Cyclobenzaprine

Effective 4/18/2022, the following products will have quantity limits added:

1. Tizanidine
2. Dantrolene
3. Baclofen
4. Farxiga